Dapagliflozin Might not Benefit Severe COVID19 Patients: DARE 19 Trial MD Bureau27 May 2021 9:00 AM ISTAlthough the primary action of sodium-glucose cotransporter-2 (SGLT2) inhibitors is on glucose and sodium reabsorption in the proximal convoluted...
SGLT2 inhibitor dapagliflozin significantly impacts urine metabolome in diabetics: Study Medha Baranwal18 April 2021 2:27 PM ISTGreece: Dapagliflozin treatment is associated with a significant change in urine metabolome in patients with type 2 diabetes (T2D) independent of...
New algorithm to sequence drugs for heart failure dr. Abhimanyu Uppal5 March 2021 9:45 AM ISTManagement of heart failure with reduced ejection fraction (HFrEF) has witnessed some major developments in the past 2 decades with the addition of...
SGLT2i in heart failure: Time to lose the clinical inertia. dr. Abhimanyu Uppal23 Feb 2021 6:15 AM ISTThe landmark trial data from DAPA-HF, EMPEROR-reduced, and SOLOIST-WHF has provided compelling evidence for the addition of SGLT2i as a new pillar of...
Health Minister discusses side-effects of SGLT-2 inhibitors in the parliament Meghna A Singhania8 Feb 2021 4:10 PM ISTNew Delhi: With the rising incidence of diabetes in the country, SGLT-2 inhibitors have emerged as one of the preferred modality of treatment....
Canagliflozin may Reduce Risk of Anemia in Diabetic Patients with CKD: Lancet Dr Kartikeya Kohli6 Feb 2021 11:30 AM ISTAnemia is a common accompaniment to diabetes, particularly in those with albuminuria or reduced renal function. In a study published in The LANCET...
SGLT-2 inhibitors significantly lower risk of Atrial Fibrillation: Study Dr Satabdi Saha4 Feb 2021 9:45 AM ISTA recent review published in Diabetes, Obesity & Metabolism and based on a clinical trial suggests that there is a significantly lower risk of...
Empagliflozin Improves Heart Failure with rEF in Nondiabetic patients: Study MD Bureau31 Jan 2021 3:18 PM ISTIn patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk of hospitalization for heart failure by 30% to...
SGLT2 inhibitors may trigger rare complications for COVID-19 patients Hina Zahid30 Dec 2020 11:15 AM ISTDiabetes is a known risk factor for morbidity and mortality related to COVID-19. In diabetes patients, rare but severe complications, like the...
Canagliflozin has kidney-protective effects in patients with advanced kidney disease Dr Kartikeya Kohli20 Nov 2020 10:57 PM ISTWashington, DC - Researchers have found in Subgroup Analysis of the Randomized CREDENCE Trial, that the diabetes drug canagliflozin slowed kidney...
Drug combo controls blood sugar, weight and BP in Diabetics: Study Dr. Kamal Kant Kohli3 Nov 2020 12:00 PM ISTPHILADELPHIA - Researchers at Thomas Jefferson University have found in a new multi-center double-blind, phase 3, randomized controlled trial that ...
ESC update: Empagliflozin Cuts risk of Hospitalization, CV Mortality in HFrEF: EMPEROR Hina Zahid29 Aug 2020 11:45 AM ISTSophia Antipolis, France - Empagliflozin is second SGLT2 inhibitor after dapagliflozin to show a significant benefit in the treatment of reduced...
